AU6266899A - Methods for producing human tumor antigen specific antibodies - Google Patents

Methods for producing human tumor antigen specific antibodies

Info

Publication number: AU6266899A
Authority: AU; Australia
Prior art keywords: methods; specific antibodies; tumor antigen; human tumor; antigen specific
Prior art date: 1998-10-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU62668/99A

Inventor

Michael Pfreundschuh

Ugur Sahin

Ozlem Tureci

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ludwig Institute for Cancer Research Ltd

Original Assignee

Ludwig Institute for Cancer Research Ltd

Ludwig Cancer Research

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-05

Filing date

1999-09-28

Publication date

2000-04-26

1999-09-28 Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd

2000-04-26 Publication of AU6266899A publication Critical patent/AU6266899A/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU62668/99A 1998-10-05 1999-09-28 Methods for producing human tumor antigen specific antibodies Abandoned AU6266899A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10314098P	1998-10-05	1998-10-05
US60103140		1998-10-05
PCT/US1999/022314 WO2000020460A1 (en)	1998-10-05	1999-09-28	Methods for producing human tumor antigen specific antibodies

Publications (1)

Publication Number	Publication Date
AU6266899A true AU6266899A (en)	2000-04-26

Family

ID=22293605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU62668/99A Abandoned AU6266899A (en)	1998-10-05	1999-09-28	Methods for producing human tumor antigen specific antibodies

Country Status (3)

Country	Link
EP (1)	EP1117691A1 (en)
AU (1)	AU6266899A (en)
WO (1)	WO2000020460A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2378949B (en) *	2001-08-16	2005-09-07	Morten Steen Hanefeld Dziegiel	Recombinant anti-plasmodium falciparum antibodies
AT411262B (en)	2001-09-27	2003-11-25	Wolff Klaus Dr	HUMAN ENDOGENIC RETROVIRUS
US8029803B2 (en) *	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
US8025873B2 (en)	2002-06-20	2011-09-27	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
US8008076B2 (en)	2004-04-27	2011-08-30	Chugai Seiyaku Kabushiki Kaisha	Method of producing a nucleic acid encoding an antibody
FR2890859B1 (en) *	2005-09-21	2012-12-21	Oreal	DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION
ES2637214T3 (en)	2007-03-13	2017-10-11	Universität Zürich	Specific human monoclonal antibody for each tumor
JP5797403B2 (en) *	2007-08-03	2015-10-21	エムユーエスシーファウンデーションフォーリサーチディベロップメント	Human monoclonal antibody and method for producing the same
US20110091896A1 (en) *	2008-06-04	2011-04-21	Shizuoka Prefecture	Method for analysis/identification of antibody gene at one-cell level
CN101885758B (en) *	2009-05-11	2014-04-30	中国医学科学院肿瘤研究所	Auto-antigen epitope and encoding gene and application thereof
JP2014518889A (en) *	2011-06-03	2014-08-07	シーティーアトランティックリミテッド	MAGEA3 binding antibody
EP2724157B1 (en) *	2011-06-27	2017-03-08	Valneva	Method for screening cells
KR20240013282A (en)	2015-06-10	2024-01-30	이뮤너티바이오, 인크.	Modified nk-92 cells for treating cancer
US11571469B2 (en)	2016-01-07	2023-02-07	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
KR20190049887A (en)	2016-09-29	2019-05-09	난트케이웨스트, 인크.	HLA class I-deficient NK-92 cells with reduced immunogenicity
EP3565889B1 (en)	2017-01-06	2025-03-26	ImmunityBio, Inc.	Genetically modified nk-92 cells with decreased cd96/tigit expression
EP3703735A1 (en)	2017-11-01	2020-09-09	Nantkwest, Inc.	Nk-92 cells to stimulate anti-cancer vaccine
US20210040451A1 (en)	2018-01-31	2021-02-11	Nantkwest, Inc.	Use of 5% human albumin in wash and harvest media
EP3743446A1 (en)	2018-03-12	2020-12-02	Nantkwest, Inc.	Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
KR102587512B1 (en)	2018-05-22	2023-10-11	이뮤너티바이오, 인크.	Optimization of NK-92 cell growth using poloxamers
CN119432756A (en)	2018-05-22	2025-02-14	免疫生物公司	FC-ε CAR
KR20210011977A (en)	2018-05-22	2021-02-02	난트케이웨스트, 인크.	Basal medium for growing NK-92 cells
US20210267190A1 (en)	2018-07-10	2021-09-02	Nantkwest, Inc.	Cryopreservation
KR102778139B1 (en)	2018-07-10	2025-03-10	이뮤너티바이오, 인크.	Generating cik nkt cells from cord blood
US20210293787A1 (en)	2018-08-01	2021-09-23	Nantkwest, Inc.	Combined invasion and cytotoxicity assay using chemokine secreting target cells
WO2020027832A1 (en)	2018-08-01	2020-02-06	Nantkwest, Inc.	Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
CN113164519B (en)	2018-08-01	2025-01-10	南克维斯特公司	Tetracistronic system containing homing receptors or cytokines and chimeric antigen receptors for genetic modification of immunotherapy
KR102520488B1 (en)	2018-11-06	2023-04-10	난트퀘스트, 인크.	CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS
US12109238B2 (en)	2018-11-06	2024-10-08	Immunitybio, Inc.	Chimeric antigen receptor-modified NK-92 cells
WO2020112669A1 (en)	2018-11-26	2020-06-04	Nantkwest, Inc.	Il-2 dependent nk-92 cells with stable fc receptor expression
US11230699B2 (en)	2020-01-28	2022-01-25	Immunitybio, Inc.	Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
US20240415964A1 (en)	2021-11-02	2024-12-19	Immunitybio, Inc.	Natural killer cells for chordoma therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994011507A2 (en) *	1992-11-19	1994-05-26	Gingeras Thomas R	Production of monoclonal recombinant antibodies without the use of hybridomas by in vitro spleen fragment culture combined with isothermal self-sustained sequence replication of rna

1999
- 1999-09-28 EP EP99949891A patent/EP1117691A1/en not_active Withdrawn
- 1999-09-28 WO PCT/US1999/022314 patent/WO2000020460A1/en not_active Application Discontinuation
- 1999-09-28 AU AU62668/99A patent/AU6266899A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1117691A1 (en)	2001-07-25
WO2000020460A1 (en)	2000-04-13

Publication	Publication Date	Title
AU6266899A (en)	2000-04-26	Methods for producing human tumor antigen specific antibodies
AU1462300A (en)	2000-05-22	Human pan-hcv human monoclonal antibodies
AU1704099A (en)	1999-06-15	Monoclonal human natural antibodies
TWI365193B (en)	2012-06-01	Human antibodies that bind human il-12 and methods for producing
ZA9810130B (en)	1999-05-06	Tumor-specific antigens methods for their production and their use for imunization and diagnosis
AU2001256325A1 (en)	2001-09-24	Human and humanized fap-alpha-specific antibodies
AU5686698A (en)	1998-06-10	Methods for the production of chicken monoclonal antibodies
AU2948199A (en)	1999-10-18	Breast cancer antigen
AU9374198A (en)	1999-03-29	Methods for producing human antibodies in scid mice using dendritic cells
EP0977590A4 (en)	2001-03-14	Human monoclonal antibodies
AU7572198A (en)	1998-12-08	Tumor-associated antigen
AU2452301A (en)	2001-07-03	Protein methylarginine-specific antibodies
GB9804065D0 (en)	1998-04-22	Tumour associated antigen 791Tgp72
AU5046700A (en)	2000-12-18	Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
ZA941645B (en)	1995-01-13	Antibodies specifically reactive against human prostate specific antigen.
AU3416599A (en)	1999-10-18	Casb414: antigen overexpressed in several tumors
AU2001245552A1 (en)	2001-09-17	Transcutaneous immunization for large particulate antigens
AU1809695A (en)	1995-09-04	Tumor associated monoclonal antibody 123av16
AU7128098A (en)	1998-11-11	Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
AU2169797A (en)	1997-10-17	Improved production of antibodies through the use of antigen antibody complexes
AU4775899A (en)	2000-01-17	Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
AU1370300A (en)	2001-06-12	Antigen-binding fragments specific for tumor associated antigens
AU1443900A (en)	2000-05-01	Glycoprotein antigens, antibodies specific thereto and method for producing same
AU2004205174B2 (en)	2007-05-03	36P6D5: Secreted tumor antigen
SI1157041T1 (en)	2005-12-31	Antibodies for cancer therapy and diagnosis

Legal Events

Date	Code	Title	Description
2001-07-05	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase